Donepezil Hydrochloride
Product Images NDC 67296-2058

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 67296-2058). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (41d7651e B91a 4118 8719 Bf2f663d82a2 01)

Chemical structure of donepezil hydrochloride showing the molecular formula with a benzylpiperidine moiety connected to a methoxy-substituted indanone ring and the hydrochloride salt indicated.*

FDA Label Image

Figure 1 (41d7651e B91a 4118 8719 Bf2f663d82a2 02)

A line graph showing ADAS-cog mean change from baseline (±SE) over 30 weeks of treatment with donepezil hydrochloride 5 mg/day, 10 mg/day, and placebo. The x-axis represents weeks of drug treatment, including a placebo phase starting at week 24. The y-axis shows cognitive change from baseline with clinical improvement and decline directions indicated. Donepezil groups show less decline compared to placebo.*

FDA Label Image

Figure 2 (41d7651e B91a 4118 8719 Bf2f663d82a2 03)

A cumulative percentage chart showing the change from baseline in patient response, comparing Donepezil hydrochloride 5 mg/day, 10 mg/day, and placebo groups. The x-axis indicates change from baseline values, while the y-axis represents the cumulative percentage of patients. The graph includes marked points for 7 points, 4 points, and no change, with a table summarizing changes in ADAS-cog scores for each treatment group.*

FDA Label Image

Figure 3 (41d7651e B91a 4118 8719 Bf2f663d82a2 04)

A bar chart comparing the percentage of patients with different CIBIC-plus ratings for Donepezil hydrochloride 10 mg/day, Donepezil hydrochloride 5 mg/day, and placebo. Ratings range from markedly improved to markedly worse, displaying the distribution of patient responses across treatment groups.*

FDA Label Image

Figure 4 (41d7651e B91a 4118 8719 Bf2f663d82a2 05)

A line graph showing the ADAS-cog mean change from baseline over 15 weeks of drug treatment for donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo. The x-axis represents weeks of treatment, and the y-axis indicates cognitive change with clinical improvement above baseline and clinical decline below baseline. Donepezil groups show clinical improvement compared to placebo over time.*

FDA Label Image

Figure 5 (41d7651e B91a 4118 8719 Bf2f663d82a2 06)

A cumulative percentage of patients graph showing changes from baseline in response to Donepezil hydrochloride 5 mg/day, 10 mg/day, and placebo. The x-axis represents change from baseline, while the y-axis shows cumulative patient percentage. Treatment group data includes change in ADAS-cog scores and percentage improvement.*

FDA Label Image

Figure 6 (41d7651e B91a 4118 8719 Bf2f663d82a2 07)

A bar chart depicting the CIBIC-plus Rating outcomes in percentages of patients for three groups: Aricept 10 mg/day, Aricept 5 mg/day, and placebo. The chart shows categories along the x-axis ranging from markedly improved to markedly worse, with patient percentages on the y-axis. Data illustrates patient response distribution across these categories for each treatment group.*

FDA Label Image

Figure 7 (41d7651e B91a 4118 8719 Bf2f663d82a2 08)

A line graph displaying change from baseline in SIB (Severe Impairment Battery) scores over 6 months of drug treatment. It compares donepezil hydrochloride 10 mg/day versus placebo, showing clinical improvement for donepezil relative to baseline and decline for placebo. Error bars indicate variability at 3 and 6 months.*

FDA Label Image

Figure 8 (41d7651e B91a 4118 8719 Bf2f663d82a2 09)

A cumulative percentage of patients plot comparing donepezil hydrochloride 10 mg/day and placebo. The x-axis represents SIB (Severe Impairment Battery) change from baseline, while the y-axis shows the cumulative percentage of patients. The graph indicates treatment response distributions for both groups.*

FDA Label Image

Figure 9 (41d7651e B91a 4118 8719 Bf2f663d82a2 10)

A line graph showing the ADCS-ADL change from baseline (mean ± SE) over 6 months of treatment comparing donepezil hydrochloride 10 mg/day and placebo. The graph illustrates clinical improvement versus decline, with donepezil showing less decline than placebo over time.*

FDA Label Image

Figure 10 (41d7651e B91a 4118 8719 Bf2f663d82a2 11)

A line graph comparing the cumulative percentage of patients over changes from baseline in ADCS-ADL scores for donepezil hydrochloride 10 mg/day versus placebo. The x-axis represents ADCS-ADL change from baseline with negative values indicating decline, and the y-axis represents cumulative percentage of patients from 0 to 100%. Data points are shown with solid circles for donepezil and open squares for placebo.*

FDA Label Image

5 (41d7651e B91a 4118 8719 Bf2f663d82a2 12)

Donepezil HCl Tablets USP 5 mg label showing the package contains 30 tablets. The label includes the NDC number 43547-275-03, states prescription only (Rx only), and is produced by Zhejiang Huahai Pharmaceutical Co., Ltd., distributed by Solco Healthcare US, LLC. Storage instructions and a pharmacist dispensing note are also visible.*

FDA Label Image

10 (41d7651e B91a 4118 8719 Bf2f663d82a2 13)

Donepezil HCl Tablets USP 10 mg film-coated tablets packaging label showing a 30-tablet bottle. Label includes product name, strength, quantity, and dispensing instructions. Distributed by Solco Healthcare US, LLC. Manufacturing information for Zhejiang Huahai Pharmaceutical Co., Ltd. also visible, along with barcode and storage guidance.*

FDA Label Image

3 (Image 01)

Donepezil HCl Tablets, USP 5 mg label with NDC 43547-275-03. The label states prescription-only status and includes pharmacist dispensing instructions. Package size is 30 tablets. Manufactured by Zhejiang Huahai Pharmaceutical Technology Co., Ltd. and distributed by Solco Healthcare US, LLC. Storage instructions and patient information link are also provided.*

FDA Label Image

4 (Image 02)

Donepezil HCl Tablets USP 10 mg packaging label showing the drug name, strength, and quantity of 30 tablets. The label includes storage instructions, manufacturer Zhejiang Huahai Pharmaceutical Technology Co., Ltd., and distributor Solco Healthcare US, LLC. The label also features a barcode, NDC 43547-276, and patient information website.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.